The tumour specific antigens and tumour associated embryonic antigens expressed on chemically induced rat hepatomata and sarcomata have been shown to be different by means of blocking antibody studies. Serum from multiparous female rats contained blocking antibody which protected both tumour and embryo cells from the in vitro cytotoxic effect of lymph node cells from multiparous donors. These sera did not, however, block the cytotoxicity of lymph node cells from tumour immune rats for cells of the immunizing tumour. In addition, the tumour specific rejection antigens and embryonic antigens have been shown to have dissimilar locations in tumour cells.
AMINOAZO dye induced rat hepatomata and 3-methylcholanthrene induced rat sarcomata express tumour specific rejection antigens, defined by their capacity to elicit immunity to transplanted tumours in syngeneic recipients (Baldwin and Barker, 1967a; Baldwin et al., 1971a) . These neoantigens are characterized by a high degree of specificity so that crossreaction between tumours is uncommon (Baldwin, 1973) . These tumours also express neoantigens at the cell surface which are normally present only on embryo cells during foetal development and are immunogenic in the adult host (Baldwin, Glaves and Pimm, 1971b ; Baldwin, Glaves and Vose, 1972b, c; Baldwin et al., 1972a) . This raises the possibility that the so-called " tumour specific rejection antigens " are, in fact, re-expressed embryonic antigens. This hypothesis has been advanced in studies with hamster cells transformed with SV40 and adenovirus 31 where immunization with irradiated embryo cells can produce immunity against transplanted tumour cells (Coggin, Ambrose and Anderson, 1970; Coggin et al., 1971 ). Since the embryonic antigens detected on chemically induced rat tumours are cross-reacting (Baldwin et al., 1972b) and the tumour rejection antigens are specific for each individual tumour, it seems unlikely that this is the case. The objective of this study has been to differentiate further between the tumour specific and embryonic antigens associated with chemically induced rat tumours.
Previous studies have indicated that lymph node cells (LNC) from multiparous female rats are cytotoxic for cultured tumour cells (Baldwin et al., 1972a, b) . Similarly, LNC from rats immunized against a particular tumour are cytotoxic for cells of the immunizing tumour (Baldwin and Embleton, 1971;  Baldwin, Embleton and Robins, 1973b) . Serum from tumour immune donors also contains antibody which protects cells of the immunizing tumour from in vitro attack by LNC from tumour-immune rats (Baldwin et al., 1973b) . In this present study the ability of serum from multiparous female rats to block the cytotoxicity of multiparous and tumour immune donor LNC for tumour and embryo cells was determined, to differentiate between embryonic and tumour specific antigens.
Preliminary evidence indicated that the embryonic antigen was present in the soluble cytoplasmic protein (cell sap) fraction of tumour homogenates (Baldwin et al., 1972c) as well as being expressed at the cell surface. In order to characterize further these embryonic antigens, their localization in tumour cells has been identified using cell fractionation studies similar to those of Baldwin and Moore (1969) which established that the tumour specific rejection antigens of aminoazo dye induced hepatomata are intimately associated with the plasma membrane and are not present in soluble cytoplasmic fractions.
MATERIALS AND METHODS
Rats and tumours.-Rats of a Wistar strain maintained in this department since 1952 by continuous single line brother-sister matings were used. Their genetic identity was confirmed by routine exchange of skin grafts. Hepatomata were induced by oral administration of 4-dimethylaminoazobenzene in a low protein diet. Sarcomata were induced by the subcutaneous injection of 3-methylcholanthrene. Tumours were passaged subcutaneously in syngeneic rats of the same sex as the original host.
Serum and lymph node cell donors.-Tumour immune lymph node cells were taken from rats immunized by the implantation of multiple, heavily irradiated (15,000 rad) tumour grafts or by excision of progressively growing tumour grafts. Immunized rats rejected repeated challenge inocula of viable tumour cells which grew consistently in untreated controls. Serum and lymph node cells were also taken from rats having had at least 4 pregnancies and which were pregnant at the time of assay. Age matched virgin female rats were used as controls.
Cell cultures.-Monolayer cell lines were initiated from single cell suspensions of trypsinized tumour tissue. Cell cultures were maintained by serial subculture in Eagle's MEM supplemented with 10% calf serum and antibiotics. Embryo cell cultures were prepared by mechanical dissociation of whole, 15-day old embryos (aged by size and development (Witschi, 1956) ) dissected free of extra-embryonic membranes and maintained in Waymouth's medium supplemented with 20% foetal calf serum and antibiotics. These embryo cultures were used as a source of target cells for cytotoxicity assays between the first and sixth passage.
Blocking tests.-Blocking tests were conducted using both Falcon Microtest (No. 3034) and Microtest II (No. 3040) plates.
Both systems produced similar results and these are presented without distinction.
Microtest.-Tumour or embryo cells from monolayer cultures were plated in the wells of Falcon Microtest plates (500-750 cells/ well) in 10 ,ul volumes, dispensed using a repeating dispenser attachment on a 500 I Hamilton syringe. After 24 hours, incubation at 37°C in a humidified atmosphere of 95% air/5% CO2 to allow cell adhesion, medium was replaced by 10 ,ul aliquots of control or test serum diluted 1: 4 in MEM buffered at pH 7.3 with HEPES (40 mmol/l N-2-hydroxyethylpiperazine-N'-ethanesulphonic acid, Sigma Chemical Co.). All sera were heat inactivated at 56°C for 30 min before use. Following incubation for 60 min at 37°C, the diluted serum was removed and replaced by LNC suspensions (target: effector cell ratio 1: 75) in MEM (HEPESbuffered) supplemented with 10% calf serum.
The plates were incubated for a further 2 days before being washed, fixed and adherent cells counted.
Microtest II.-Tumour cells were plated in the wells of Falcon Microtest II plates (100 cells/well). After 24 hours incubation, medium was replaced by 0 05 ml aliquots of heat inactivated test or control serum diluted 1: 4 in MEM (HEPES-buffered).
Following incubation for 45 min at 37°C the diluted serum was removed and replaced by LNC suspensions (5 x 105 cells in 0-2 ml HEPES-buffered MEM per well). The plates were incubated for a further 45 min and 0.05 ml aliquots of 50% calf serum in HEPES-buffered MEM were added to each well. After 2 days incubation the cells were washed, fixed and stained, and adherent cells counted (Baldwin et al., 1973b) .
Cell fractionation.-Tumour, embryo and normal liver tissue were finely minced and homogenized in 0-25 mol/l sucrose containing 2 mmol/l CaCl2, 2 mmol/l Mg C12 and 1 mmol/l NaHCO3 (pH 7.6) using an Ultraturrax tissue homogenizer operated at approximately -1 maximum output. Remaining connective tissue debris was removed by filtration through 60-mesh stainless steel screens and homogenization continued at 5-min intervals with cooling until approximately 90% cellular disruption was achieved.
Homogenates were centrifuged at 1000 g for 30 min to remove cells and nuclei and the 1000 g supernatants further centrifuged at 78,000 g for 30 min. The sediment was taken as an extranuclear membrane fraction (ENM) and the supernatant as the soluble cytoplasmic protein (cell sap) fraction. All samples were dialysed against phosphate buffered saline (pH 7-3) before storage at -200C.
Membrane immunofluorescence tests.-The indirect membrane immunofluorescence test was performed on viable tumour and embryo cells in suspension as previously described (Baldwin and Barker, 1967b; Baldwin et al., 1972b) . Fluorescence indices were calculated from the proportions of unstained cells exposed to test serum compared with control sera and a value of 0-30 or greater was taken to represent a significant reaction. Antigen assay.-Subcellular fractions were assayed for embryonic antigen activity by their capacity to absorb antibody from multiparous rat sera reacting with hepatoma D23 cells, as detected by the membrane immunofluorescence test (Baldwin and Moore, 1969; Baldwin and Glaves, 1972) . Antigenic activity was indicated by a reduction of the fluorescent index to below the value taken to reflect a significant reaction (0-30) with absorbed serum, as compared with multiparous rat serum diluted with equivalent volumes of phosphate buffered saline.
Immunization of rats with ENM and cell sap fractions.-Syngeneic rats were immunized with tumour or embryo ENM fractions suspended in medium 199, pH 7-6, or concentrated soluble fractions, by repeated subcutaneous injections at 7-14 day intervals. Rats received 4 such injections so that each received 30-50 mg protein ENM or 30-120 mg soluble cell sap protein. Animals were bled by cardiac puncture under ether anaesthesia, the serum collected and stored at -20°C before testing for reactivity against embryo cells by membrane immunofluorescence tests.
Protein analysis.-Protein was determined by the method of Lowry et al. (1951) .
RESULTS

Blocking of multiparous donor lymph node cell cytotoxicity by multiparous sera
Lymph node cells from multiparous rats were cytotoxic for hepatoma D23 cells and, as shown in Table I , this cytotoxicity was abrogated by pre-exposure of plated tumour cells to heat inactivated sera from multiparous donors. Six of 11 sera were effective in significantly reducing LNC cytotoxicity producing abrogations of 49.8% to 77.8%. (Table II) , pretreatment of plated target cells with .5 of 13 multiparous sera produced significant abrogation of multiparous LNC cytotoxicity (41.1% to 100%) compared with the effect of normal virgin control sera. In addition, LNC from multiparous rats were cytotoxic' for cultured 15-day old embryo cells and this cytotoxicity was blocked by pretreatment of the target cells with multiparous rat serum (Table III) . Thus, 4 of 5 sera significantly reduced the cytotoxic index of multiparous LNC for embryo cell targets by 73.1% to 100%.
Blocking of tumour immune lymph node cell cytotoxicity by multiparous sera Table IV shows the results of tests in which hepatoma D23 target cells were incubated with sera from multiparous rats before treatment with LNC from rats specifically sensitized to this hepatoma. None of the 10 sera significantly reduced the specific cytotoxicity of these LNC for cells of the immunizing tumour. Similar results were obtained in studies using sarcoma Mc7 as target cells (Table  V) LNC from tumour immunized rats are cytotoxic for cultured 15-day old rat embryo cells (Baldwin, Glaves and Vose, 1974) . This cytotoxicity could be abrogated by incubating the embryo target cells with serum from multiparous rats before treatment with LNC from tumour immune rats (Table VI) . Three of 5 multiparous rat sera significantly reduced the cytotoxicity of hepatoma D30 immune LNC for 15-day old embryo cells by 60% to 100%. Similarly, 3 of 7 sera from multiparous rats reduced the cytotoxicity of hepatoma D23 immune LNC for embryo cells.
Subcellular localization of embryonic antigen
Rat antisera to both tumour and embryo cell sap and extranuclear membrane fractions reacted in immunofluorescence tests with 15-and 16-day old rat embryo cells (Table VII) . Whilst antisera to membrane fractions also reacted with tumour cells, antisera to cell sap fractions did not. The reactivity of anti-tumour cell sap antisera with embryo cells is taken to indicate that the cell sap as well as the plasma membrane contains embryonic antigen. Embryonic antigen can be detected at the plasma membrane of tumour cells by membrane immunofluorescence staining with multiparous rat serum (Baldwin et al., 1972a, b) . As shown in Table VIII , this reaction with hepatoma D23 cells could be abolished or significantly reduced by absorption of the serum with either hepatoma D23 or 14-day old embryo cell sap (20-50 mg cell sap protein/ml antiserum). Absorption with cell sap fractions from 19-and 20-day old embryos (25 and ] 8 mg protein/ml antiserum respectively) did not reduce significantly the F.I. of multiparous rat serum with hepatoma D23. Absorption of MPS with cell sap fractions of adult liver (up to 79 mg protein/ml antiserum) were also ineffective in reducing fluorescent membrane staining.
DISCUSSION
During pregnancy, multiparous female rats are exposed to antigens expressed on the cells of the foetus which may elicit the formation of sensitized lymphoid cells. If tumour cells express both embryonic and tumour specific antigens, tumour immunization may result in the development of separate lymphoid cell populations directed against both of these specificities. Differential blocking of tumour or embryo cells with multiparous rat serum from attack by these lymph node cell populations provides an approach for distinguishing between tumour specific and embryonic antigens.
Sera from multiparous rats known to contain antibody directed against tumour associated embryonic antigens (Baldwin et al., 1971b; 1972a, b) can block cell surface embryonic antigens on both embryo and tumour target cells. Plated cells are not then susceptible to cytotoxic attack by embryonic antigen sensitized lymph node cells. Immunization of syngeneic rats with tumour cells also elicits lymph node cells sensitized towards the tumour associated embryonic antigens since these LNC are cytotoxic in vitro for embryo cells (Baldwin et al., 1974) . As demonstrated in the present study, this cytotoxicity can be blocked by pretreating embryo cells with multiparous rat serum, thus offering further evidence that immunization with tumour cells elicits an immune response to embryonic antigens.
It has previously been argued (Baldwin et al., 1971b; 1972a, b) on grounds of antigen specificities that the individually distinct tumour rejection antigens on rat hepatomata and sarcomata differ from the cross-reacting tumour associated embryonic antigens. This postulate is further supported by the data reported in this paper since pretreatment of plated tumour cells with multiparous rat serum did not block them from the cytotoxic attack of specifically sensitized LNC from tumour immune rats. Since these LNC preparations contain cells cytotoxic for embryo cells and this reaction can be blocked by multiparous serum, it is concluded that tumour immunization produced different LNC populations sensitized to embryonic and tumour specific antigens. The cytotoxicity mediated by LNC reacting with embryonic antigens expressed on either embryo or tumour cells will be blocked by multiparous serum. The cytotoxicity mediated by LNC reacting with the individually distinct tumour antigens will then be restricted to tumour cells and, as evidenced by the present study, will not be blocked by multiparous serum. The reactivity, however, can be specifically blocked by serum from tumour immune rats (Baldwin et al., 1973b) . In this case, tumour immune serum blocks only cells of the immunizing tumour from cytotoxic attack by tumour immune LNC, again indicating that individual tumour antigens are being detected.
Further differentiation between the individual tumour specific and embryonic antigens on rat hepatomata and sarcomata is provided by the experiments on their subeellular localization. The tumour specific antigens expressed on rat hepatomata (Baldwin and Moore, 1969; Baldwin, Harris and Price, 1973d) and sarcomata (Baldwin and Pimm, unpublished findings) are intimately associated with the plasma membrane. Following cell rupture, tumour specific antigen, defined by its capacity to absorb antibody from syngeneic tumour immune serum, is isolated only in cell membrane fractions. The soluble cytoplasmic fraction does not contain detectable antigen. This is further evidenced by the failure of immunization of syngeneic rats with cytoplasmic fractions to elicit tumour specific antibody, although membrane fractions retain immunogenicity (Baldwin and Moore, 1969; Baldwin, Embleton and Moore, 1973a) . Also, release of tumour specific antigen from isolated membrane fractions can be effected only by disruptive procedures such as papain solubilization (Baldwin and Glaves, 1972; Baldwin et al., 1973d) .
The methods used to demonstrate embryonic antigens on tumour cells (lymph node cell cytotoxicity, membrane immunofluorescence staining of bound immunoglobulin and complement dependent serum cytotoxicity) establish that these antigens are expressed at the cell surface membrane (Baldwin et al., 1971b; 1972b) . However, following rupture of either tumour or embryo cells, embryonic antigen is detectable in the cytoplasmic fraction. This is demonstrated by the capacity of cell sap fractions to neutralize antibody in multiparous rat serum reacting with cell membrane expressed antigens on tumour cells. Also, immunization of syngeneic rats with tumour and 14-day old embryo cell saps elicits antibody to embryonic antigens so that sera from these rats consistently gave positive immunofluorescence staining with embryo cells. Significantly, as already indicated, there is no concomitant production of tumour specific antibody. These findings suggest that the tumour associated embryonic antigens may be primarily intracellular proteins showing transient expression at the cell surface or, alternatively, they may be weakly associated plasma membrane products readily detaching on cell rupture.
If the embryonic antigen is primarily an intracellular product, two possibilities could account for its appearance at the cell surface. It may be continuously synthesized in the cytoplasm and leak out or be secreted on to the cell surface. Alternatively, the antigen detected at the plasma membrane may be synthesized there from a large pool of preformed determinants in the cytoplasm. The former seems more likely upon comparison with the properties of other cell surface expressed antigens. Thus, as already discussed, the tumour rejection antigen is detectable only at the plasma membrane and no antigen activity codld be shown in the cell cytoplasm. Siniilarly, recent work on HL-A histocompatibility antigens suggests that HL-A2 is synthesized de novo at the plasma membrane and that a large pool of preformed determinants is not present in the cells (Turner, Strominger and Sanderson, 1972) . Earlier studies on mouse H-2 antigens also indicated that disrupted cells had only slightly more alloantibody absorbing capacity than an equivalent number of intact cells (Haughton, 1966) . Confirmation that a precursor: product relationship between the cytoplasmic and cell surface expressed embryonic antigens must, however, await precise biochemical characterization of these components.
The finding of two separate neoantigen expressions at the cell surface of rat hepatomata and sarcomata is in agreement with studies by Ting et al., (1972) on SV40 and polyoma induced mouse tumours. By differential absorption of antibody from syngeneic antisera to foetal or tumour cells, it was established that the tumour rejection antigens and embryonic antigens were different. Also, in the studies of Thomson and Alexander (1973) and Menard, Calnaghi and Della Porta (1973) two antigenic specificities were detected on polycyclic hydrocarbon induced sarcomata. One of these, the tumour specific transplantation antigen, was characterized by its individual tumour specificity, whilst the second was shared between different tumours and present on embryo cells. This separation of the embryonic and tumour specific antigens may not apply in all situations, however, and Coggin et al. (1970 Coggin et al. ( , 1971 suggest that in SV40 virus induced tumours in the hamster, the two antigens may be identical since immunization with irradiated foetal tissue led to the induction of tumour immunity. In this system the status of the identity between the two antigens is not settled since females did not respond to foetal immunization as well as males, although no such disparity is evident upon immunization to tumour. Subsequent studies (Coggin and Anderson, 1972) have not resolved this disparity.
The present studies demonstrate that the tumour specific antigens, viewed as being of primary importance in tumour rejection, are different from the embryonic antigens common to cells of 14-to 16-day old embryos and tumours. It cannot be excluded, however, that the tumour specific antigens are other embryonic antigens rather than being the products of new genetic information introduced by carcinogen induced changes (Baldwin, 1973) . During foetal development there may be a multiplicity of genes coding for polypeptides, some of which may be expressed only for short times, or on a limited number of cells. Such antigenic specificities would not be detectable by the methods employed in this study so that the origin of the diverse tumour specific antigens on chemically induced tumours is still not resolved. 
